Therapeutic Antibodies and Beyond:

2010 marks the 20th anniversary of the development of antibody phage display, a technology that revolutionised antibody discovery and shaped the clinical and commercial landscape for biotherapeutics. It also caused some landmark patent disputes between companies developing antibody products. 

Phage display has joined hybridoma and humanisation technologies in making biologic drugs a reality, driving a US $41bn market in therapeutic antibodies and defining the treatment of human diseases in the 21st century. 

To celebrate the contribution of phage display to research, to human health and to commerce, John McCafferty and Debbie Allen (both formerly of Cambridge Antibody Technology), are organising a 2 day summit in Cambridge, UK, bringing together many of the pioneers of this technology.

Through a combination of platform presentations, panel discussions and debate, the conference will explore the many factors that shaped this unique technology over 20 years – and discuss its impact on science, innovation and medicine, now and for the future.

This conference marks a major milestone in the evolution of biotechnology. Bringing together some of the most prominent leaders in the phage display field, it offers a unique combination of historical retrospective and vision for the future of healthcare. It is an event of special interest to researchers in bioscience, business development professionals and biotechnology entrepreneurs alike.